

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231	
<div>1. <input checked="" type="checkbox"/> Fee Transmittal Form <i>Submit an original, and a duplicate for fee processing</i></div> <div>2. <input type="checkbox"/> Applicant claims Small Entity status, see 37 C.F.R. § 1.27</div> <div>3. <input checked="" type="checkbox"/> Specification [Total Pages 143] <i>(preferred arrangement set forth below)</i> -Descriptive title of the Invention -Cross Reference to Related Applications -Statement Regarding Fed sponsored R&D -Reference to Microfiche Appendix -Background of the Invention -Brief Summary of the Invention -Brief Description of the Drawings (if filed) -Detailed Description of the Invention (including drawings, if filed) -Claim(s) -Abstract of the Disclosure</div> <div>4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets 36]</div> <div>5. <input checked="" type="checkbox"/> Oath or Declaration [Total Sheets 2] <input checked="" type="checkbox"/> Unexecuted (original or copy) <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 19 completed)</i> <div>i. <input type="checkbox"/> <u>DELETION OF INVENTORS(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).</div></div> <div>6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</div>		<div>7. <input checked="" type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</div> <div>8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> <div>a. <input checked="" type="checkbox"/> Computer Readable Copy</div><div>b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy)</div><div>c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</div></div>	
		ACCOMPANYING APPLICATION PARTS	
		<div>9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))</div> <div>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></div> <div>11. <input type="checkbox"/> English Translation Document (if applicable)</div> <div>12. <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Copies of IDS Citations (IDS)/PTO-1449</div> <div>13. <input type="checkbox"/> Preliminary Amendment</div> <div>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></div> <div>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></div> <div>16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(i). Applicant must attach form PTO/SB/35 or its equivalent</div> <div>17. <input type="checkbox"/> Other:</div>	
18. If a CONTINUING APPLICATION , check appropriate box and supply the requisite information: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No: filed.			
19. CORRESPONDENCE ADDRESS			
Customer Number: 		20583 <i>(Insert Customer No. or Attach bar code label here)</i>	
or [] Correspondence address below			
NAME			
ADDRESS			
CITY		STATE	ZIP CODE
COUNTRY	TELEPHONE		FAX

PENNIE & EDMONDS LLP
 COUNSELLORS AT LAW
 1155 Avenue of Americas
 New York, N.Y. 10036-2711

ATTORNEY DOCKET NO. 10271-037-999Date: December 10, 2001

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Solomon R. Langermann; Scott J. Hultgren; Chia-Suei Hung; and Julie Bouckaert Executed on: Unexecuted

Title of Invention: Mutant Proteins, High Potency Antibodies, and FimCH Crystal Structure

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	32	-20	12	\$18.00 each	\$ 216.00
Independent	7	-3	4	\$84.00 each	\$ 336.00
Minimum Fee					\$ 740.00
Multiple Dependency Fee If Applicable (\$280.00)					\$ 270.00
Total					\$ 1,562.00
Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$ 0.00
Total Filing Fee					\$ 1,562.00

- ☐ **DO NOT PUBLISH.** I hereby certify that the invention disclosed in the attached application **has not and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
- ☒ Priority of application nos. 60/254,353 filed on December 8, 2000 and 60/301,878 filed on June 29, 2001 is claimed under 35 U.S.C. § 119.
- ☐ The certified copy of the priority application has been filed in application no. file 1
- ☐ Amend the specification by inserting before the first line the following sentence: This is a continuation-in-part of application no. filed .

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Anthony M. Insogna 35,203
 Anthony M. Insogna (Reg. No.)
 PENNIE & EDMONDS LLP

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

Reg No.
 40,922

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Langermann *et al.*

Application No.: To be Assigned

Art Unit: Not Yet Assigned

Filed: On Even Date Herewith

Examiner: Not Yet Assigned

For: Mutant Proteins, High Potency Inhibitory
Antibodies, and FimCH Crystal Structure

Atty Docket No.: 1(271-037

TRANSMITTAL OF SEQUENCE LISTING

Assistant Commissioner for Patents
Washington, DC 20231

S I R :

In connection with the above-identified application, and in accordance with 37 C.F.R. § 1.821, Applicant submits herewith a Sequence Listing in paper and computer-readable format pursuant to 37 C.F.R. § 1.821(c) and (e).

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same. I hereby state that the submission herein under 37 C.F.R. § 1.821(g) does not include new matter.

Respectfully submitted,

Date December 10, 2001

Anthony M. Insogna^{35,203}
Anthony M. Insogna (Reg. No.)

By Margaret B. Rivdarian
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2111
(212) 790-9090
Pg No. 40,922

Enclosures

Express Mail No. FL 477 032 527 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Langermann *et al.*

Application No.: To be Assigned

Art Unit: Not Yet Assigned

Filed: On Even Date Herewith

Examiner: Not Yet Assigned

For: Mutant Proteins, High Potency Inhibitory
Antibodies, and FimCH Crystal Structure

Atty Docket No.: 10271-037

TRANSMITTAL OF TABLES ON CD-ROM

Assistant Commissioner for Patents
Washington, DC 20231

S I R :

In connection with the above-identified application, and in accordance with 37 C.F.R. § 1.58, Applicant submits herewith two tables in computer-readable format pursuant to 37 C.F.R. § 1.52(e) and §1.58.

I hereby state that the content of 'Copy 1' and 'Copy 2' of the CD-ROM in computer-readable format, submitted in accordance with 37 C.F.R. § 1.52(e) and §1.58, are the same.

Respectfully submitted,

Date December 10, 2001

Anthony M. Insogna^{35,203}
(Reg. No.)

by Margaret B. Rouvanel
PENNIE & EDMONDS LLP Reg No. 40,922
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures